JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia
暂无分享,去创建一个
M. D. Den Boer | R. Pieters | C. Zwaan | J. Boer | H. D. de Groot-Kruseman | M. Horstmann | M. Koudijs | N. Besselink | C. van de Ven | E. Steeghs | I. Jerchel | Willemieke de Goffau-Nobel | A. Q. Hoogkamer | A. Boeree | M. D. den Boer | Nicolle J. M. Besselink | Alex Q. Hoogkamer | Aurélie Boeree
[1] M. Loh,et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. , 2017, Blood.
[2] M. Warr,et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. , 2017, Blood.
[3] M. Loh,et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2017, Blood.
[4] O. Haas,et al. Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia , 2016, Leukemia.
[5] M. D. Den Boer,et al. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia , 2016, Oncotarget.
[6] R. Pieters,et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Taki,et al. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan , 2016, Blood Cancer Journal.
[8] Z. Ge,et al. A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis , 2016, Haematologica.
[9] M. D. Den Boer,et al. B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. , 2015, Blood.
[10] M. Loh,et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011) , 2015, Pediatric blood & cancer.
[11] W. Evans,et al. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures , 2015, Haematologica.
[12] A. Letai,et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. , 2015, Cancer cell.
[13] Jing Ma,et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia , 2015, Nature Communications.
[14] M. D. Den Boer,et al. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia. , 2015, Blood.
[15] W. Evans,et al. BCR-ABL 1-like cases in pediatric acute lymphoblastic leukemia : a comparison between DCOG / Erasmus MC and COG / St , 2015 .
[16] A. Letai,et al. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis , 2014, Science Signaling.
[17] M. Loh,et al. Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia , 2014, Molecular Cancer Therapeutics.
[18] Heather L. Mulder,et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.
[19] S. Antonarakis,et al. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations , 2014, Nature Communications.
[20] R. Pieters,et al. Disturbed CXCR4/CXCL12 axis in paediatric precursor B‐cell acute lymphoblastic leukaemia , 2014, British journal of haematology.
[21] R. Levine,et al. Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors , 2014, Clinical Cancer Research.
[22] Travis J Cohoon,et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. , 2014, Cancer discovery.
[23] R. Pieters,et al. Disturbed CXCR4/CXCL12 Axis In Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia , 2013 .
[24] W. Evans,et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. , 2013, Blood.
[25] L. Zeng,et al. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability. , 2013, International journal of biological macromolecules.
[26] S. Mittelman,et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. , 2013, Cancer research.
[27] G. Escherich,et al. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07‐03 , 2013, Pediatric blood & cancer.
[28] Tejaswi Koganti,et al. Analysis of Patterns of Gene Expression Variation within and between Ethnic Populations in Pediatric B-ALL , 2013, Cancer informatics.
[29] M. Loh,et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.
[30] Ryan D. Morin,et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.
[31] N. Heisterkamp,et al. Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia , 2012, Oncoimmunology.
[32] M. Loh,et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. , 2012, Blood.
[33] J. Vizmanos,et al. Transforming and Tumorigenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosine-Kinase , 2012, PloS one.
[34] Eric Vangrevelinghe,et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition , 2011, The Journal of experimental medicine.
[35] A. Poulsen,et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies , 2011, Leukemia.
[36] J. Tchinda,et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. , 2011, Blood.
[37] M. D. Den Boer,et al. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97) , 2011, Haematologica.
[38] Hein Putter,et al. mstate: An R Package for the Analysis of Competing Risks and Multi-State Models , 2011 .
[39] P. Koduru,et al. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia. , 2010, Leukemia research.
[40] S. Shepard,et al. Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans , 2010, Drug Metabolism and Disposition.
[41] Takashi Akasaka,et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. , 2010, Blood.
[42] J. Downing,et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.
[43] E. Lam,et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis , 2010, Haematologica.
[44] B. Druker,et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. , 2010, Blood.
[45] K. Anderson,et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity , 2010, Nature Medicine.
[46] E. Domany,et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. , 2010, Blood.
[47] P. D. Dal Cin,et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[48] J. Downing,et al. Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.
[49] W. Kamps,et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). , 2009, The Lancet. Oncology.
[50] Takashi Akasaka,et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.
[51] I. Behrmann,et al. SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling , 2009, Oncogene.
[52] D. Scadden,et al. The leukemic stem cell niche: current concepts and therapeutic opportunities. , 2009, Blood.
[53] M. Loh,et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[54] W. Evans,et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.
[55] Christopher B. Miller,et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. , 2009, The New England journal of medicine.
[56] K. Anderson,et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. , 2009, Blood.
[57] Angela C. Colmone,et al. Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells , 2008, Science.
[58] G. Wainreb,et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome , 2008, The Lancet.
[59] G. Fan,et al. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. , 2008, Human pathology.
[60] J. Downing,et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. , 2007, The Journal of clinical investigation.
[61] Asim Khwaja,et al. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells , 2006, British journal of haematology.
[62] M. D. Boer,et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] O. Silvennoinen,et al. The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction* , 2002, The Journal of Biological Chemistry.
[64] J. Hermans,et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996) , 2002, Leukemia.
[65] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[66] P. Grambsch,et al. A Package for Survival Analysis in S , 1994 .